Literature DB >> 6633190

Use of the hazard rate to schedule follow-up exams efficiently. An optimization approach to patient management.

A J Dwyer, J M Prewitt, J G Ecker, J Plunkett.   

Abstract

The problem of surveillance for metastasis in a cancer patient is modeled as an allocation problem. The hazard rate of metastasis appearing determines the efficient scheduling of follow-up exams. An optimal schedule of follow-up exams is shown to be dependent on the hazard rate, K, and D. K relates the cost of testing to the benefit of early detection. It diminishes as benefit increases or cost diminishes. D is the time by which a metastasis' detection by testing precedes its clinical presentation. Hence it is a direct measure of the effectiveness of testing. The optimal testing frequency = (hazard rate/2K)1/2. Testing may be stopped when the hazard rate drops below 2K/D2. Tests need never be routinely scheduled if the intervals between tests exceed D in length.

Entities:  

Mesh:

Year:  1983        PMID: 6633190     DOI: 10.1177/0272989X8300300211

Source DB:  PubMed          Journal:  Med Decis Making        ISSN: 0272-989X            Impact factor:   2.583


  3 in total

1.  Bayesian inference for the lead time in periodic cancer screening.

Authors:  Dongfeng Wu; Gary L Rosner; Lyle D Broemeling
Journal:  Biometrics       Date:  2007-09       Impact factor: 2.571

2.  Hazard rates for dysplasia and cancer in ulcerative colitis. Results from a surveillance program.

Authors:  B A Lashner; M D Silverstein; S B Hanauer
Journal:  Dig Dis Sci       Date:  1989-10       Impact factor: 3.199

3.  Risk-Dependent Conditional Survival and Failure Hazard After Radiotherapy for Early-Stage Extranodal Natural Killer/T-Cell Lymphoma.

Authors:  Xin Liu; Tao Wu; Su-Yu Zhu; Mei Shi; Hang Su; Ying Wang; Xia He; Li-Ming Xu; Zhi-Yong Yuan; Li-Ling Zhang; Gang Wu; Bao-Lin Qu; Li-Ting Qian; Xiao-Rong Hou; Fu-Quan Zhang; Yu-Jing Zhang; Yuan Zhu; Jian-Zhong Cao; Sheng-Min Lan; Jun-Xin Wu; Shu-Nan Qi; Yong Yang; Ye-Xiong Li
Journal:  JAMA Netw Open       Date:  2019-03-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.